← All trials
NCT01638416
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2012
- Primary completion
- Apr 30, 2017
- Completion date
- Jun 30, 2017
- First posted
- Jul 11, 2012
- Last posted
- Oct 22, 2020
- Enrollment
- 4994
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Monash UniversityLead sponsor
- Monash UniversityReponsible party - principal investigator
- Australian Red CrossCollaborator
- Finnish Red CrossCollaborator
- Irish Blood Transfusion ServiceCollaborator
- King Abdul-Aziz UniversityCollaborator
- National University of IrelandCollaborator
- Monash UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.